Correlation Between Day One and Monopar Therapeutics
Can any of the company-specific risk be diversified away by investing in both Day One and Monopar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Day One and Monopar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Day One Biopharmaceuticals and Monopar Therapeutics, you can compare the effects of market volatilities on Day One and Monopar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Day One with a short position of Monopar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Day One and Monopar Therapeutics.
Diversification Opportunities for Day One and Monopar Therapeutics
-0.15 | Correlation Coefficient |
Good diversification
The 3 months correlation between Day and Monopar is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Day One Biopharmaceuticals and Monopar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monopar Therapeutics and Day One is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Day One Biopharmaceuticals are associated (or correlated) with Monopar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monopar Therapeutics has no effect on the direction of Day One i.e., Day One and Monopar Therapeutics go up and down completely randomly.
Pair Corralation between Day One and Monopar Therapeutics
Given the investment horizon of 90 days Day One Biopharmaceuticals is expected to under-perform the Monopar Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Day One Biopharmaceuticals is 2.01 times less risky than Monopar Therapeutics. The stock trades about -0.27 of its potential returns per unit of risk. The Monopar Therapeutics is currently generating about 0.24 of returns per unit of risk over similar time horizon. If you would invest 1,923 in Monopar Therapeutics on September 14, 2024 and sell it today you would earn a total of 502.00 from holding Monopar Therapeutics or generate 26.11% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Day One Biopharmaceuticals vs. Monopar Therapeutics
Performance |
| Timeline |
| Day One Biopharmaceu |
| Monopar Therapeutics |
Day One and Monopar Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Day One and Monopar Therapeutics
The main advantage of trading using opposite Day One and Monopar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Day One position performs unexpectedly, Monopar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will offset losses from the drop in Monopar Therapeutics' long position.| Day One vs. X4 Pharmaceuticals | Day One vs. Inozyme Pharma | Day One vs. Acumen Pharmaceuticals | Day One vs. Mereo BioPharma Group |
| Monopar Therapeutics vs. Puma Biotechnology | Monopar Therapeutics vs. Iovance Biotherapeutics | Monopar Therapeutics vs. Day One Biopharmaceuticals | Monopar Therapeutics vs. Inozyme Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |